Beijing Guohong Biomedical Technology Co. Ltd. has presented new inhibitors of proto-oncogene tyrosine-protein kinase Src, hepatocyte growth factor receptor and more.
Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd. has synthesized new antibody-drug conjugates (ADC) or antigen binding fragments targeting claudin 18 (CLDN18) and linked to cytotoxic drug reported to be useful for the treatment of cancer.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has presented new Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Institute of Organic Chemistry and Zai Lab (US) LLC have described new receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis, psoriasis, inflammatory bowel disease, inflammation, macular degeneration, systemic lupus erythematosus and arthritis, among other disorders.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome, Costello syndrome, neurofibromatosis type 1, Noonan syndrome and Legius syndrome (neurofibromatosis type 1-like syndrome).
Jacobio Pharmaceuticals Co. Ltd. has synthesized new protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer.
Nanchang Helioeast Technology Co. Ltd. has identified new oxa-azaspiro compounds acting as lysine-specific histone demethylase 1A (KDM1A; LSD1) inhibitors reported to be useful for the treatment of acute myeloid leukemia.
RSS
